RU2010116184A - NEW ANTIBODIES - Google Patents

NEW ANTIBODIES Download PDF

Info

Publication number
RU2010116184A
RU2010116184A RU2010116184/10A RU2010116184A RU2010116184A RU 2010116184 A RU2010116184 A RU 2010116184A RU 2010116184/10 A RU2010116184/10 A RU 2010116184/10A RU 2010116184 A RU2010116184 A RU 2010116184A RU 2010116184 A RU2010116184 A RU 2010116184A
Authority
RU
Russia
Prior art keywords
antibody
seq
amino acid
sequence
variable domain
Prior art date
Application number
RU2010116184/10A
Other languages
Russian (ru)
Other versions
RU2490277C2 (en
Inventor
Вэй-Чин ЛЯН (US)
Вэй-Чин ЛЯН
Грегори Д. ПЛАУМАН (US)
Грегори Д. ПЛАУМАН
Янь У (US)
Янь У
Вэйлань Е (US)
Вэйлань Е
Original Assignee
Дженентек, Инк. (Us)
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. (Us), Дженентек, Инк. filed Critical Дженентек, Инк. (Us)
Publication of RU2010116184A publication Critical patent/RU2010116184A/en
Application granted granted Critical
Publication of RU2490277C2 publication Critical patent/RU2490277C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

1. Антитело против α5β1, содержащее последовательность вариабельного домена легкой цепи, содержащую (1) LHVR1, содержащую аминокислотную последовательность KASQ-N/S-VGSDVA (SEQ ID NO: 10), (2) LHVR2, содержащую аминокислотную последовательность STSYRYS (SEQ ID NO: 11), и (3) LHVR3, содержащую аминокислотную последовательность QQY-N/S-SYPFT (SEQ ID NO: 12), и последовательность вариабельного домена тяжелой цепи, содержащую (1) HHVR1, содержащую аминокислотную последовательность GYTF-T/S-DYYLY (SEQ ID NO: 13), (2) HHVR2, содержащую аминокислотную последовательность GISPS-N/S-GGTTF-N/A-D-N/A-FE-N/G (SEQ ID NO: 14), и (3) HHVR3, содержащую аминокислотную последовательность DAYGDWYFDV (SEQ ID NO: 15). ! 2. Антитело против α5β1, содержащее вариабельный домен легкой цепи, обладающий последовательностью, указанной в любой из SEQ ID NO: 1, 2, 3 или 4, или вариант этого, и вариабельный домен тяжелой цепи, обладающий последовательностью, указанной в любой из SEQ ID NO:5, 6, 7, 8 или 9, или вариант этого. ! 3. Антитело по п.2, где вариабельный домен легкой цепи обладает последовательностью, указанной в SEQ ID NO: 3, и вариабельный домен тяжелой цепи обладает последовательностью, указанной в SEQ ID NO:8. ! 4. Антитело по п.2, где вариант последовательности вариабельного домена тяжелой цепи содержит замену аминокислоты в остатке, выбранном из группы, состоящей из 30, 48, 49, 54, 60, 62, 65, 66, 67 и 69. ! 5. Антитело по п.2, где вариабельный домен легкой цепи содержит замену аминокислоты в остатке, выбранном из группы, состоящей из 28, 46 и 92. ! 6. Антитело по п.4, где замена аминокислоты выбрана из группы, состоящей из T30S, I48V, G49S, N54S, N60A, N62A, N62S, N65G, K66R, A67F и L69I. ! 7. Антитело по п.5, где вариабельный домен легкой цепи содержит замену аминокислоты, выбранную из группы, состоящей из N28S, T46L и N92S. ! 8. Ан 1. An anti-α5β1 antibody comprising a light chain variable domain sequence comprising (1) LHVR1 containing the amino acid sequence KASQ-N / S-VGSDVA (SEQ ID NO: 10), (2) LHVR2 containing the amino acid sequence STSYRYS (SEQ ID NO : 11), and (3) LHVR3 containing the amino acid sequence QQY-N / S-SYPFT (SEQ ID NO: 12), and the sequence of the variable domain of the heavy chain containing (1) HHVR1 containing the amino acid sequence GYTF-T / S- DYYLY (SEQ ID NO: 13), (2) HHVR2 containing the amino acid sequence GISPS-N / S-GGTTF-N / ADN / A-FE-N / G (SEQ ID NO: 14), and (3) HHVR3, containing conductive amino acid sequence DAYGDWYFDV (SEQ ID NO: 15). ! 2. Antibody against α5β1 containing the variable domain of the light chain having the sequence specified in any of SEQ ID NO: 1, 2, 3 or 4, or a variant thereof, and the variable domain of the heavy chain having the sequence specified in any of SEQ ID NO: 5, 6, 7, 8, or 9, or a variant of this. ! 3. The antibody according to claim 2, where the variable domain of the light chain has the sequence specified in SEQ ID NO: 3, and the variable domain of the heavy chain has the sequence specified in SEQ ID NO: 8. ! 4. The antibody according to claim 2, where the sequence variant of the variable domain of the heavy chain contains an amino acid substitution in the residue selected from the group consisting of 30, 48, 49, 54, 60, 62, 65, 66, 67 and 69.! 5. The antibody according to claim 2, where the variable domain of the light chain contains an amino acid substitution in the residue selected from the group consisting of 28, 46 and 92.! 6. The antibody according to claim 4, where the amino acid substitution is selected from the group consisting of T30S, I48V, G49S, N54S, N60A, N62A, N62S, N65G, K66R, A67F and L69I. ! 7. The antibody according to claim 5, where the variable domain of the light chain contains an amino acid substitution selected from the group consisting of N28S, T46L and N92S. ! 8. An

Claims (36)

1. Антитело против α5β1, содержащее последовательность вариабельного домена легкой цепи, содержащую (1) LHVR1, содержащую аминокислотную последовательность KASQ-N/S-VGSDVA (SEQ ID NO: 10), (2) LHVR2, содержащую аминокислотную последовательность STSYRYS (SEQ ID NO: 11), и (3) LHVR3, содержащую аминокислотную последовательность QQY-N/S-SYPFT (SEQ ID NO: 12), и последовательность вариабельного домена тяжелой цепи, содержащую (1) HHVR1, содержащую аминокислотную последовательность GYTF-T/S-DYYLY (SEQ ID NO: 13), (2) HHVR2, содержащую аминокислотную последовательность GISPS-N/S-GGTTF-N/A-D-N/A-FE-N/G (SEQ ID NO: 14), и (3) HHVR3, содержащую аминокислотную последовательность DAYGDWYFDV (SEQ ID NO: 15).1. An anti-α5β1 antibody comprising a light chain variable domain sequence comprising (1) LHVR1 containing the amino acid sequence KASQ-N / S-VGSDVA (SEQ ID NO: 10), (2) LHVR2 containing the amino acid sequence STSYRYS (SEQ ID NO : 11), and (3) LHVR3 containing the amino acid sequence QQY-N / S-SYPFT (SEQ ID NO: 12), and the sequence of the variable domain of the heavy chain containing (1) HHVR1 containing the amino acid sequence GYTF-T / S- DYYLY (SEQ ID NO: 13), (2) HHVR2 containing the amino acid sequence GISPS-N / S-GGTTF-N / ADN / A-FE-N / G (SEQ ID NO: 14), and (3) HHVR3, containing conductive amino acid sequence DAYGDWYFDV (SEQ ID NO: 15). 2. Антитело против α5β1, содержащее вариабельный домен легкой цепи, обладающий последовательностью, указанной в любой из SEQ ID NO: 1, 2, 3 или 4, или вариант этого, и вариабельный домен тяжелой цепи, обладающий последовательностью, указанной в любой из SEQ ID NO:5, 6, 7, 8 или 9, или вариант этого.2. Antibody against α5β1 containing the variable domain of the light chain having the sequence specified in any of SEQ ID NO: 1, 2, 3 or 4, or a variant thereof, and the variable domain of the heavy chain having the sequence specified in any of SEQ ID NO: 5, 6, 7, 8, or 9, or a variant of this. 3. Антитело по п.2, где вариабельный домен легкой цепи обладает последовательностью, указанной в SEQ ID NO: 3, и вариабельный домен тяжелой цепи обладает последовательностью, указанной в SEQ ID NO:8.3. The antibody according to claim 2, where the variable domain of the light chain has the sequence specified in SEQ ID NO: 3, and the variable domain of the heavy chain has the sequence specified in SEQ ID NO: 8. 4. Антитело по п.2, где вариант последовательности вариабельного домена тяжелой цепи содержит замену аминокислоты в остатке, выбранном из группы, состоящей из 30, 48, 49, 54, 60, 62, 65, 66, 67 и 69.4. The antibody according to claim 2, where the variant sequence of the variable domain of the heavy chain contains an amino acid substitution in the residue selected from the group consisting of 30, 48, 49, 54, 60, 62, 65, 66, 67 and 69. 5. Антитело по п.2, где вариабельный домен легкой цепи содержит замену аминокислоты в остатке, выбранном из группы, состоящей из 28, 46 и 92.5. The antibody according to claim 2, where the variable domain of the light chain contains an amino acid substitution in the residue selected from the group consisting of 28, 46 and 92. 6. Антитело по п.4, где замена аминокислоты выбрана из группы, состоящей из T30S, I48V, G49S, N54S, N60A, N62A, N62S, N65G, K66R, A67F и L69I.6. The antibody according to claim 4, where the amino acid substitution is selected from the group consisting of T30S, I48V, G49S, N54S, N60A, N62A, N62S, N65G, K66R, A67F and L69I. 7. Антитело по п.5, где вариабельный домен легкой цепи содержит замену аминокислоты, выбранную из группы, состоящей из N28S, T46L и N92S.7. The antibody according to claim 5, where the variable domain of the light chain contains an amino acid substitution selected from the group consisting of N28S, T46L and N92S. 8. Антитело по пп.1, 2 или 3, где антитело не связывает альфаVбета3, или альфаVбета5, или альфаVбета1.8. The antibody according to claims 1, 2 or 3, where the antibody does not bind alphaVbeta3, or alphaVbeta5, or alphaVbeta1. 9. Антитело по п.1, где антитело содержит последовательность Fc из IgG человека.9. The antibody according to claim 1, where the antibody contains an Fc sequence of human IgG. 10. Антитело по п.9, где IgG человека представляет собой hIgG1 или hIgG4.10. The antibody of claim 9, wherein the human IgG is hIgG1 or hIgG4. 11. Антитело по п.9, где антитело содержит последовательность Fc с отсутствием эффекторной функции антителозависимой клеточной цитотоксичности (ADCC).11. The antibody according to claim 9, where the antibody contains an Fc sequence with no effector function of antibody-dependent cell cytotoxicity (ADCC). 12. Антитело по п.11, где последовательность Fc содержит замену D265A.12. The antibody according to claim 11, where the Fc sequence contains a replacement D265A. 13. Антитело по п.1, где антитело выбрано из группы, состоящей из Fab, Fab', F(ab)'2, одноцепочечного Fv (scFv), Fv-фрагмента; диатела и линейного антитела.13. The antibody according to claim 1, where the antibody is selected from the group consisting of Fab, Fab ', F (ab)' 2 , single-chain Fv (scFv), Fv fragment; diabodies and linear antibodies. 14. Антитело по п.1, где антитело представляет собой мультиспецифическое антитело.14. The antibody according to claim 1, where the antibody is a multispecific antibody. 15. Антитело по п.1, конъюгированное с лекарственным средством.15. The antibody according to claim 1, conjugated to a drug. 16. Антитело по п.15, где лекарственное средство выбрано из группы, состоящей из цитотоксического средства, радиоактивного изотопа и химиотерапевтического средства.16. The antibody of claim 15, wherein the drug is selected from the group consisting of a cytotoxic agent, a radioactive isotope, and a chemotherapeutic agent. 17. Антитело по п.1, конъюгированное с меткой.17. The antibody according to claim 1, conjugated with a label. 18. Антитело по п.17, где метка выбрана из группы, состоящей из радиоактивного изотопа, флуоресцентного красителя и фермента.18. The antibody of claim 17, wherein the label is selected from the group consisting of a radioactive isotope, a fluorescent dye, and an enzyme. 19. Выделенная молекула нуклеиновой кислоты, кодирующая антитело по п.1.19. The selected nucleic acid molecule encoding the antibody according to claim 1. 20. Экспрессирующий вектор, кодирующий молекулу нуклеиновой кислоты по п.19.20. An expression vector encoding a nucleic acid molecule according to claim 19. 21. Клетка, содержащая экспрессирующий вектор по п.20.21. A cell containing the expression vector of claim 20. 22. Способ получения антитела, включающий в себя культивирование клетки по п.21 и выделение антитела из культуры клеток.22. A method for producing an antibody, comprising culturing a cell according to claim 21 and isolating the antibody from the cell culture. 23. Композиция, содержащая антитело по п.1, и фармацевтически приемлемый носитель.23. The composition containing the antibody according to claim 1, and a pharmaceutically acceptable carrier. 24. Способ детекции белка α5βl в образце от пациента посредством приведения в контакт антитела по п.1 с образцом и детекции антитела против α5β1, связанного с белком α5βl.24. A method for detecting α5βl protein in a sample from a patient by contacting the antibody of claim 1 with the sample and detecting an anti-α5β1 antibody bound to α5βl protein. 25. Способ по п.24, где антитело используют в иммуногистохимическом анализе (IHC) или анализе ELISA.25. The method according to paragraph 24, where the antibody is used in immunohistochemical analysis (IHC) or ELISA. 26. Применение антитела по п.1 для изготовления лекарственного средства для ингибирования ангиогенеза и/или проницаемости или просачивания сосудов у субъекта.26. The use of an antibody according to claim 1 for the manufacture of a medicament for inhibiting angiogenesis and / or vascular permeability or leakage in a subject. 27. Применение антитела по п.1 для изготовления лекарственного средства для лечения заболевания у субъекта, где при заболевании присутствует аномальный ангиогенез или проницаемость или просачивание сосудов.27. The use of an antibody according to claim 1 for the manufacture of a medicament for treating a disease in a subject, where the disease has abnormal angiogenesis or vascular permeability or leakage. 28. Способ ингибирования ангиогенеза и/или проницаемости или просачивания сосудов у субъекта, страдающего заболеванием, включающий в себя введение антагониста VEGF и антитела против α5βl по п.1.28. A method of inhibiting angiogenesis and / or vascular permeability or leakage in a subject suffering from a disease, comprising administering a VEGF antagonist and an anti-α5βl antibody of claim 1. 29. Способ лечения рака у субъекта, включающий в себя введение антагониста VEGF и антитела против α5β1 по п.1.29. A method of treating cancer in a subject, comprising administering a VEGF antagonist and an anti-α5β1 antibody of claim 1. 30. Способ лечения глазного заболевания у субъекта, включающий в себя введение антагониста VEGF и антитела против α5β1 по п.1.30. A method of treating ocular disease in a subject, comprising administering a VEGF antagonist and an anti-α5β1 antibody according to claim 1. 31. Способ лечения аутоиммунного заболевания у субъекта, включающий в себя введение антагониста VEGF и антитела против α5β1 по п.1.31. A method of treating an autoimmune disease in a subject, comprising administering a VEGF antagonist and an anti-α5β1 antibody of claim 1. 32. Способ по п.30, где субъект не обладает повышенными уровнями α5βl в пораженной заболеванием ткани по сравнению с тканью субъекта, не страдающего заболеванием.32. The method according to clause 30, where the subject does not have elevated levels of α5βl in the diseased tissue compared with the tissue of a subject not suffering from a disease. 33. Способ по любому из пп. 28-32, где субъекту дополнительно вводят лекарственное средство, выбранное из группы, состоящей из антинеопластического средства, химиотерапевтического средства, ингибирующего рост средства и цитотоксического средства.33. The method according to any one of paragraphs. 28-32, where the subject is additionally administered a drug selected from the group consisting of an antineoplastic agent, a chemotherapeutic agent that inhibits the growth of the agent, and a cytotoxic agent. 34. Способ по любому из пп. 28-32, где антагонист VEGF можно конкурентно ингибировать связыванием VEGF человека антителом Авастин®.34. The method according to any one of paragraphs. 28-32, where the VEGF antagonist can be competitively inhibited by binding of human VEGF antibody Avastin®. 35. Способ по п.34, где антагонист VEGF представляет собой антитело Авастин®.35. The method according to clause 34, where the VEGF antagonist is an Avastin® antibody. 36. Композиция, содержащая антагонист VEGF, антитело по п.1 и фармацевтически приемлемый ингибитор. 36. A composition comprising a VEGF antagonist, an antibody according to claim 1 and a pharmaceutically acceptable inhibitor.
RU2010116184/10A 2007-09-26 2008-09-25 Novel antibodies RU2490277C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97547107P 2007-09-26 2007-09-26
US60/975,471 2007-09-26
PCT/US2008/077622 WO2009042746A1 (en) 2007-09-26 2008-09-25 Novel antibodies

Publications (2)

Publication Number Publication Date
RU2010116184A true RU2010116184A (en) 2011-11-10
RU2490277C2 RU2490277C2 (en) 2013-08-20

Family

ID=40329277

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010116184/10A RU2490277C2 (en) 2007-09-26 2008-09-25 Novel antibodies

Country Status (22)

Country Link
US (3) US7973138B2 (en)
EP (1) EP2200700B1 (en)
JP (1) JP2011501656A (en)
KR (1) KR20100065162A (en)
CN (1) CN101888878B (en)
AR (1) AR066170A1 (en)
AU (1) AU2008304452B2 (en)
BR (1) BRPI0816049A2 (en)
CA (1) CA2698609A1 (en)
CL (1) CL2008002856A1 (en)
CO (1) CO6260094A2 (en)
DK (1) DK2200700T3 (en)
HR (1) HRP20160308T1 (en)
HU (1) HUE027911T2 (en)
MX (1) MX2010003325A (en)
MY (1) MY151191A (en)
NZ (1) NZ584838A (en)
PE (1) PE20091029A1 (en)
RU (1) RU2490277C2 (en)
SI (1) SI2200700T1 (en)
TW (1) TWI547503B (en)
WO (1) WO2009042746A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010003325A (en) 2007-09-26 2010-04-09 Genentech Inc Novel antibodies.
PE20120770A1 (en) 2009-03-25 2012-07-10 Genentech Inc ANTI alpha5ß1 ANTIBODIES WITH ACTIVITY ON GLIOBLASTOMAS
CA2665956A1 (en) * 2009-05-07 2010-11-07 Samir Patel Combination treatment for ocular diseases
CA2760246A1 (en) 2009-05-08 2010-11-11 Weilan Ye Humanized anti-egfl7 antibodies and methods using same
US8956600B2 (en) 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
WO2012154983A2 (en) 2011-05-10 2012-11-15 Biocare Medical, Llc Systems and methods for anti-pax8 antibodies
US20130058926A1 (en) * 2011-08-30 2013-03-07 Shiseido Company, Ltd. Method for alleviating and/or preventing skin reddening
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
WO2013152011A1 (en) * 2012-04-02 2013-10-10 Ab Biosciences, Inc. Novel human control antibodies and uses therefor
EP2847231B1 (en) 2012-05-10 2019-07-10 Bioatla LLC Multi-specific monoclonal antibodies
JP6324970B2 (en) 2012-09-27 2018-05-23 バイオケア メディカル， エルエルシー Anti-uroplakin II antibody system and method
WO2014100220A2 (en) 2012-12-18 2014-06-26 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
WO2014105910A1 (en) 2012-12-26 2014-07-03 Oncosynergy, Inc. ANTI- INTEGRIN β1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF
CA2898239A1 (en) 2013-01-23 2014-07-31 Syddansk Universitet Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors
WO2014122143A1 (en) * 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
ES2720483T3 (en) 2013-02-28 2019-07-22 Biocare Medical Llc Anti p40 antibody systems and procedures
WO2015051320A2 (en) 2013-10-03 2015-04-09 Biocare Medical, Llc Anti-sox10 antibody systems and methods
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN108712911A (en) 2015-12-30 2018-10-26 科达制药股份有限公司 Antibody and its conjugate
CN108693004B (en) * 2018-05-24 2020-08-04 中国农业科学院农业质量标准与检测技术研究所 Method for detecting whether rapeseed meal is doped with antibiotic filter residues or not
US11384146B2 (en) * 2019-04-01 2022-07-12 Curia Ip Holdings, Llc BTLA-binding antibodies for modulating immune response and treating disease
JP2022553640A (en) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド Methods of treating eye disorders
CN114688461A (en) * 2020-12-31 2022-07-01 青岛海尔施特劳斯水设备有限公司 Water leakage detection method and system
CN113133431A (en) * 2021-02-25 2021-07-20 中南大学 Establishment method, model and application of chronic ocular hypertension combined long-axis animal model
CN114073996B (en) * 2021-11-24 2023-04-14 中山大学 Nested micro-well array chip and preparation method thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540933A (en) 1985-05-31 1996-07-30 La Jolla Cancer Research Foundation Isolation and use of fibronectin receptor
EP0330506A3 (en) 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
US20020146410A1 (en) 1992-05-22 2002-10-10 Helmut Eckert Monoclonal antibodies and their use
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5627263A (en) 1993-11-24 1997-05-06 La Jolla Cancer Research Foundation Integrin-binding peptides
ATE244306T1 (en) 1994-12-20 2003-07-15 Merck Patent Gmbh MONOCLONAL ANTIBODY AGAINST THE ALPHA-V INTEGRIN
KR20010034327A (en) 1998-01-23 2001-04-25 플레믹 크리스티안 MONOCLONAL ANTIBODY ANTI αν-INTEGRIN AND ITS USE TO INHIBIT ανβ6-INTEGRIN ATTACHMENT TO FIBRONECTIN
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
WO1999058139A2 (en) 1998-05-08 1999-11-18 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB9909392D0 (en) 1999-04-24 1999-06-23 Imp Cancer Res Tech Treatment, imaging and diagnosis of disease
US20020019330A1 (en) 1999-08-11 2002-02-14 Richard Murray Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
US20040009494A1 (en) 1999-08-11 2004-01-15 Richard Murray Novel methods of diagnosis of angiogenesis and other conditions, compositions, and the methods of screening for modulators
EP1204764A2 (en) 1999-08-11 2002-05-15 EOS Biotechnology, Inc. Methods of screening for angiogenesis modulators
US20020015970A1 (en) 1999-08-11 2002-02-07 Richard Murray Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
US20030152926A1 (en) 1999-08-11 2003-08-14 Eos Biotechnology, Inc. Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20040259152A1 (en) 2000-02-22 2004-12-23 Richard Murray Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
JP2004531249A (en) 2001-02-14 2004-10-14 プロテイン デザイン ラブス インコーポレイティド Method for diagnosing angiogenesis, composition, and method for screening angiogenesis modulator
WO2002086443A2 (en) 2001-04-18 2002-10-31 Protein Design Labs, Inc Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
WO2002098358A2 (en) 2001-06-04 2002-12-12 Eos Biotechnology, Inc. Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
EP1517998A2 (en) 2001-06-18 2005-03-30 EOS Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7189507B2 (en) 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US20040033495A1 (en) 2001-08-03 2004-02-19 Eos Biotechnology, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20070042360A1 (en) 2001-09-17 2007-02-22 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
EP1434881A4 (en) 2001-09-17 2005-10-26 Protein Design Labs Inc Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
US20030232350A1 (en) 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20060241067A1 (en) 2002-06-25 2006-10-26 Varner Judith A Methods For inhibiting angiogenesis, cell migration, cell adhesion, and cell survival
AU2003299529A1 (en) 2002-07-16 2004-06-03 University Of Medicine And Dentistry Of New Jersey Alpha 5 beta 1 and its ability to regulate the cell survival pathway
CN100369930C (en) * 2002-11-26 2008-02-20 Pdl生物制药股份有限公司 Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis
WO2004048938A2 (en) 2002-11-26 2004-06-10 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US7285268B2 (en) 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
CA2520121A1 (en) 2003-04-03 2004-10-21 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
CA2560508A1 (en) 2004-03-24 2005-10-06 Pdl Biopharma, Inc. Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
US20060008415A1 (en) 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
PT1819359E (en) 2004-12-09 2015-05-28 Janssen Biotech Inc Anti-integrin immunoconjugates, methods of their production and their use
CN101360736A (en) 2005-11-23 2009-02-04 阿斯利康(瑞典)有限公司 L-alanine derivatives
JP2009516729A (en) 2005-11-23 2009-04-23 アストラゼネカ アクチボラグ L-phenylalanine derivative
CN101379028A (en) 2006-02-09 2009-03-04 阿斯利康(瑞典)有限公司 Chemical compounds
BRPI0709338A2 (en) * 2006-03-21 2011-07-12 Genentech Inc antibody, isolated nucleic acid molecule, cell, compositions, alpha5beta1 protein detection method, antibody use, treatment methods, kit, use of a composition, use of an alpha5beta antagonist, and use of a vegf antagonist
KR20090027218A (en) 2006-05-24 2009-03-16 바이엘 쉐링 파마 악티엔게젤샤프트 HIGH AFFINITY HUMAN AND HUMANIZED ANTI-alpha5beta1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY
MX2010003325A (en) 2007-09-26 2010-04-09 Genentech Inc Novel antibodies.
BRPI0906387A2 (en) 2008-02-05 2015-07-07 Bristol Myers Squibb Co Alpha 5 - beta 1 antibodies and their uses

Also Published As

Publication number Publication date
NZ584838A (en) 2012-08-31
CO6260094A2 (en) 2011-03-22
CL2008002856A1 (en) 2009-01-16
US7973138B2 (en) 2011-07-05
TW200924794A (en) 2009-06-16
MX2010003325A (en) 2010-04-09
WO2009042746A1 (en) 2009-04-02
US20120148572A1 (en) 2012-06-14
RU2490277C2 (en) 2013-08-20
CA2698609A1 (en) 2009-04-02
US20090098112A1 (en) 2009-04-16
DK2200700T3 (en) 2016-04-11
HRP20160308T1 (en) 2016-04-22
PE20091029A1 (en) 2009-08-19
EP2200700A1 (en) 2010-06-30
MY151191A (en) 2014-04-30
CN101888878B (en) 2014-05-21
JP2011501656A (en) 2011-01-13
CN101888878A (en) 2010-11-17
SI2200700T1 (en) 2016-04-29
AU2008304452B2 (en) 2014-01-16
US20120156129A1 (en) 2012-06-21
TWI547503B (en) 2016-09-01
EP2200700B1 (en) 2016-01-13
US8840887B2 (en) 2014-09-23
BRPI0816049A2 (en) 2019-09-24
US9284376B2 (en) 2016-03-15
AU2008304452A1 (en) 2009-04-02
KR20100065162A (en) 2010-06-15
AR066170A1 (en) 2009-07-29
HUE027911T2 (en) 2016-11-28

Similar Documents

Publication Publication Date Title
RU2010116184A (en) NEW ANTIBODIES
US10836827B2 (en) Antibodies specific to glycosylated PD-L1 and methods of use thereof
JP5631733B2 (en) Anti-EpCAM antibodies and uses thereof
US11660352B2 (en) Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof
EP3487883B1 (en) Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
KR101854443B1 (en) Anti-her2 antibody and conjugate thereof
RU2413735C2 (en) Antibodies and related molecules binding with proteins 161p2f10b
RU2013125306A (en) BINDING PROTEINS SPECIFIC TO THE INSULIN-LIKE GROWTH FACTORS AND THEIR USE
JP2010537671A5 (en)
JP2011501656A5 (en)
WO2011083088A2 (en) Methods for treating colorectal cancer
WO2011083090A2 (en) Methods for treating breast cancer
RU2009148600A (en) CHIMERAL AND HUMANIZED ANTIBODIES TO CD44 THAT ARE MEDIATED BY CYTOTOXICITY AGAINST CANCER CELLS
RU2006146666A (en) ANTIBODIES AND RELATED MOLECULES BINDING PSCA PROTEINS
CN112111008A (en) anti-CD 73 antibodies and uses thereof
JP2014530209A (en) Anti-ICAM-1 antibodies for treating multiple myeloma-related disorders
EP4055058A1 (en) Binding proteins to cub domain-containing protein (cdcp1)
WO2018232164A1 (en) Antibody drug conjugates that bind lgr5
US9914768B2 (en) Anti-S100A7 antibodies for the treatment and diagnosis of cancer
EP4293044A1 (en) Anti-trpv6 monoclonal antibody and application thereof
RU2761638C1 (en) Antibodies against the programmed death ligand (pd-l1) and application thereof
CN107446049B (en) Monoclonal antibody targeting human liver cancer stem cells and application thereof
CN107118276B (en) Monoclonal antibody targeting human tumor stem cells and application thereof
US20160002347A1 (en) Pyruvate kinase m2 neutralizing antibodies for inhibiting angiogenesis
US11933786B2 (en) Antibodies specific to glycosylated PD-L1 and methods of use thereof

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160926